SPDR S&P Biotech (NYSEARCA:XBI) was the target of some unusual options trading activity on Friday. Stock investors purchased 13,002 call options on the company. This represents an increase of approximately 194% compared to the average volume of 4,420 call options.

A number of institutional investors have recently made changes to their positions in XBI. Russell Investments Group Ltd. raised its position in SPDR S&P Biotech by 61.7% in the second quarter. Russell Investments Group Ltd. now owns 49,141 shares of the exchange traded fund’s stock worth $3,792,000 after purchasing an additional 18,746 shares in the last quarter. Bray Capital Advisors boosted its holdings in SPDR S&P Biotech by 120.3% during the second quarter. Bray Capital Advisors now owns 15,610 shares of the exchange traded fund’s stock valued at $1,205,000 after purchasing an additional 8,525 shares in the last quarter. Boston Advisors LLC acquired a new stake in SPDR S&P Biotech during the second quarter valued at approximately $213,000. Meridian Wealth Management LLC bought a new stake in shares of SPDR S&P Biotech in the 2nd quarter valued at approximately $432,000. Finally, FineMark National Bank & Trust grew its stake in shares of SPDR S&P Biotech by 7.4% in the 2nd quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock valued at $402,000 after purchasing an additional 360 shares during the period.

Shares of SPDR S&P Biotech (NYSEARCA:XBI) opened at 87.78 on Wednesday. The firm’s 50-day moving average is $82.15 and its 200 day moving average is $75.26. SPDR S&P Biotech has a 1-year low of $53.15 and a 1-year high of $88.46.

The company also recently announced a quarterly dividend, which was paid on Monday, September 25th. Investors of record on Monday, September 18th were paid a $0.037 dividend. The ex-dividend date of this dividend was Friday, September 15th. This represents a $0.15 dividend on an annualized basis and a dividend yield of 0.17%.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/10/04/traders-buy-large-volume-of-call-options-on-spdr-sp-biotech-xbi.html.

About SPDR S&P Biotech

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Receive News & Stock Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related stocks with our FREE daily email newsletter.